Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide vs Hydrochlorothiazide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Thiazide Diuretic

Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide

First FDA approval: 2025-05-15

Thiazide Diuretic

Hydrochlorothiazide

Brand: INZIRQO

First FDA approval: 1973-01-12

Lowest NADACAcquisition cost floor across all NDCs

$0.863Per unit

$0.012Per unit

Average NADACAcross all dosage forms and strengths

$1.13Up to $1.26

$0.091Up to $4.45

Generic manufacturersActive ANDA holders — FDA Orange Book

732 total ANDAs filed

1127 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$122.0MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

27.6M9.2M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$4Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

2Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Active shortageSee drug profile

Generic availableFDA Orange Book

Yes7 manufacturers

Yes11 manufacturers